Teva Pharmaceutical Industries Limited (TEVA) is listed on NYSE and operates in the Drug Manufacturers - Specialty & Generic industry (Healthcare sector).
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treat...
| Rating | Analysts |
|---|---|
| Strong Buy | 0 |
| Buy | 22 |
| Hold | 20 |
| Sell | 4 |
| Strong Sell | 0 |
Teva Pharmaceutical Industries Limited is a global pharmaceutical company based in Tel Aviv-Yafo, Israel, established in 1901. It specializes in the development, manufacturing, marketing, and distribution of generic and specialty medicines, as well as biopharmaceutical products. Teva operates in North America, Europe, and other international markets. The company's product portfolio includes sterile products, hormones, high-potency drugs, and cytotoxic substances available in various dosage forms such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. Teva also produces active pharmaceutical ingredients. The company focuses on therapeutic areas including the central nervous system, pain management, respiratory conditions, and oncology. Notable products include Copaxone for multiple sclerosis, AJOVY for migraine prevention, and AUSTEDO for tardive dyskinesia and Huntington disease-related chorea. In the respiratory segment, Teva offers treatments for asthma and chronic obstructive pulmonary disease. Its oncology offerings include Bendeka, Treanda, and Granix. Teva collaborates with MedinCell on long-acting injectable products, including a risperidone suspension for schizophrenia treatment.
Over the past three fiscal years, the company has demonstrated a consistent increase in revenue, growing at a 4.4% CAGR from $15.85 billion in 2023 to $17.26 billion in 2025. This revenue growth was accompanied by a significant improvement in profitability metrics. The gross margin expanded by 3.5 percentage points, reaching 51.8% in 2025, while the operating margin showed a notable turnaround, increasing by 9.8 percentage points to 12.5%. This improvement in operating efficiency was mirrored in the net margin, which shifted from -3.5% in 2023 to a positive 8.2% in 2025, indicating a successful profitability turnaround. Cash generation also improved, with free cash flow (FCF) growing at a 16.8% CAGR, reaching $1.15 billion in 2025, and the FCF margin increasing by 1.3 percentage points to 6.7%. The company's cash conversion ratio (CCR) improved significantly, reaching 1.16, suggesting that earnings are increasingly backed by actual cash. Additionally, the net debt position decreased consistently, from $16.93 billion in 2023 to $13.83 billion in 2025, reflecting improved financial health. However, the share count increased by 4.8%, which partially diluted per-share gains. Despite these positive trends, interest coverage remains thin at 2.3x, indicating potential challenges in meeting interest obligations. Overall, the company has shown strong operational and financial improvements, although some caution is warranted regarding leverage and share dilution.
Recent developments for Teva Pharmaceutical Industries Ltd. have been marked by significant analyst activity and strategic initiatives. On April 20, AE Wealth Management LLC disclosed a reduction in its holdings of Teva by 6% during the fourth quarter, with its stake valued at approximately $2.31 million. This move follows a period of increased interest, as the firm had previously acquired new stakes worth $255,000 and $238,000 in the second quarter. Meanwhile, on April 13, Seeking Alpha initiated a 'Buy' rating on Teva, suggesting that the market is undervaluing the company's pipeline potential. In terms of strategic initiatives, Teva launched the Home Ground™ Schizophrenia Community on April 15, an online resource aimed at supporting individuals with schizophrenia and their care partners. This initiative underscores Teva's commitment to addressing mental health challenges through community engagement. Additionally, Teva continues to advance its biosimilar portfolio, with recent FDA approval for PONLIMSI™ and filing acceptance for a biosimilar candidate to Xolair®. These developments are part of Teva's broader 'Pivot to Growth' strategy, highlighting its transformation into a leading biopharmaceutical company.